EBR Systems (ASX:EBR) said it expects US Food and Drug Administration (FDA) approval for its wireless, cardiac resynchronization therapy system WiSE by April, according to a Tuesday filing with the Australian bourse.

Pending regulatory approval, EBR is planning for the commercial launch of the system in the second half of the year, the filing said.

Price (AUD): $2.05, Change: $+0.075, Percent Change: +3.80%